PDCD1 and melanoma: Also, a comprehensive analysis of biomarkers indicating the likelihood of survival or response to anti-CTLA-4 and anti-PD-1 monotherapy in patients with advanced melanoma revealed a consistent negative correlation between Treg cells and response rates, PFS, and OS in most of the studies [60].